<u>Cohort profile: The Pregnancy, Arsenic, and Immune Response (PAIR) Study, a</u> <u>Iongitudinal pregnancy and birth cohort in rural northern Bangladesh</u>

3	Lindsay N. Avolio, ^{1†} Tyler J. S. Smith, ^{1†} Ana Navas-Acien, ² Kate Kruczynski, ¹ Nora Pisanic, ¹
4	Pranay R. Randad, ¹ Barbara Detrick, ³ Rebecca C. Fry, ⁴ Alexander van Geen, ⁵ Walter Goessler, ⁶
5	Ruth A. Karron, ⁷ Sabra L. Klein, ⁸ Elizabeth L. Ogburn, ⁹ Marsha Wills-Karp, ¹ Kelsey Alland, ⁷ Kaniz
6	Ayesha, ¹⁰ Brian Dyer, ⁷ Md. Tanvir Islam, ¹⁰ Habibat A. Oguntade, ^{7,11} Md. Hafizur Rahman, ¹⁰
7	Hasmot Ali, ¹⁰ Rezwanul Haque, ¹⁰ Saijuddin Shaikh, ¹⁰ Kerry J. Schulze, ⁷ A. K. M.
8	Muraduzzaman, ¹² A. S. M. Alamgir, ¹² Meerjady Sabrina Flora, ¹² Keith P. West Jr., ⁷ Alain B.
9	Labrique, ⁷ Christopher D. Heaney, ^{1,7,13*} for the JiVitA Maternal and Child Health and Nutrition
10	Research Project
11	
12	¹ Department of Environmental Health & Engineering, Johns Hopkins University, Baltimore, MD,
13	USA
14	² Department of Environmental Health Sciences, Columbia University, New York, NY, USA
15	³ Department of Pathology, Johns Hopkins University, Baltimore, MD, USA
16	⁴ Department of Environmental Sciences & Engineering, University of North Carolina, Chapel Hill,
17	NC, USA
18	⁵ Lamont-Doherty Earth Observatory, Columbia University, Palisades, NY, USA
19	⁶ Institute of Chemistry - Analytical Chemistry, University of Graz, Graz, Austria
20	⁷ Department of International Health, Johns Hopkins University, Baltimore, MD, USA
21	⁸ Department of Molecular Microbiology & Immunology, Johns Hopkins University, Baltimore, MD,
22	USA
23	⁹ Department of Biostatistics, Johns Hopkins University, Baltimore, MD, USA
24	¹⁰ JiVitA Maternal and Child Health and Nutrition Research Project, Gaibandha, Bangladesh
25	¹¹ Division of Epidemiology and Community Health, University of Minnesota School of Public
26	Health, Minneapolis, MN, USA

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

- ¹²Institute of Epidemiology, Disease Control, and Research, Dhaka, Bangladesh
- ¹³Department of Epidemiology, Johns Hopkins University, Baltimore, MD, USA
- 29
- ¹ LNA and TJSS contributed equally to this paper.
- 31
- 32 * Corresponding Author:
- 33 Christopher D. Heaney, PhD, MS
- 34 Johns Hopkins Bloomberg School of Public Health
- 35 615 North Wolfe Street, Room 7033B
- 36 Baltimore, MD 21205
- 37 Phone: (443) 287-4989
- 38 E-mail: cheaney1@jhu.edu
- 39

40 ABSTRACT

Purpose: Arsenic exposure and micronutrient deficiencies may alter immune reactivity to influenza vaccination in pregnant women, transplacental transfer of maternal antibodies to the fetus, and maternal and infant acute morbidity. The Pregnancy, Arsenic, and Immune Response (PAIR) Study is a longitudinal pregnancy and birth cohort designed to assess whether arsenic exposure and micronutrient deficiencies alter maternal or newborn immunity and acute morbidity following maternal seasonal influenza vaccination during pregnancy.

47 Participants: We enrolled 784 pregnant women in rural Gaibandha District in northern 48 Bangladesh between October 2018 and March 2019. Women received a guadrivalent seasonal 49 inactivated influenza vaccine at enrollment in the late first or early second trimester between 11 50 and 17 weeks of gestational age. Follow-up included up to 13 visits between enrollment and three 51 months postpartum as well as weekly telephone surveillance to ascertain influenza-like illness 52 and other acute morbidity symptoms in women and infants. Tube well drinking water and urine 53 specimens were collected to assess arsenic exposure. Of 784 women who enrolled, 736 (93.9%) 54 delivered live births and 551 (70.3%) completed follow-up visit to three months postpartum.

Findings to Date: Arsenic was $\ge 0.02 \ \mu g/L$ in 97.9% of water specimens collected from participants at enrollment. The medians (interquartile ranges) of water and urinary arsenic were 57 5.1 (0.5-25.1) $\mu g/L$ and 33.1 (19.6-56.5) $\mu g/L$, respectively. Water and urinary arsenic were 58 strongly correlated (Spearman's $\rho=0.72$) among women with water arsenic \ge median but weakly 59 correlated ($\rho=0.18$) among women with water arsenic < median.

60 **Future Plans:** The PAIR Study is well positioned to examine the effects of low-moderate arsenic

61 exposure and micronutrient deficiencies on immune outcomes in women and infants.

62 **Registration:** NCT03930017

63 INTRODUCTION

64 Arsenic exposure is a major threat to global health. About 140 million people worldwide 65 are exposed to drinking water arsenic exceeding the World Health Organization's (WHO's) 66 guideline value of 10 µg/L [1]. Arsenic causes bladder, lung, and skin cancers [2] and has been 67 associated with cardiovascular disease, diabetes mellitus, and the metabolic syndrome [3,4]. 68 Over the past decade, multiple studies have found that arsenic was associated with altered 69 cellular [5] and humoral immune responses [6-8] and increased risk of infection, acute morbidity, 70 and related mortality [9–12]. Of particular concern is immunotoxicity following exposure during 71 pregnancy and early life [13]. However, while exposure in utero has been associated with reduced 72 pathogen-specific antibody responses to some childhood vaccinations [6-8] and increased risk 73 of respiratory and gastrointestinal morbidities in children [14-21], less is known about arsenic and 74 the immune response in pregnant women and newborns during the first months of life. In addition, 75 arsenic methylation facilitated by one-carbon metabolism appears to modify arsenic toxicity for 76 certain chronic disease outcomes [22]. Arsenic methylation is known to shift during pregnancy 77 [23,24]. However, few studies of arsenic immunotoxicity have evaluated potential effect measure 78 modification by micronutrient deficiencies that influence arsenic methylation in pregnant women. 79 The WHO recommends seasonal influenza vaccination at any stage of pregnancy to 80 protect pregnant women and infants <6 months of age [25], who benefit from maternal antibodies 81 transferred across the placenta [26–28]. Since the risk of severe illness from infection by influenza 82 virus is higher in pregnant women and infants [29,30], expanding maternal vaccination against 83 influenza is imperative. If arsenic reduces the maternal antibody response to influenza vaccine or 84 transplacental transfer of maternal antibodies to the fetus, however, additional interventions may 85 be needed. Yet relations among arsenic exposure, micronutrient deficiencies, antibody responses

86 to influenza vaccination in pregnant women, transplacental transfer of maternal antibodies, and

87 influenza-like illness (ILI) and other acute morbidities remain understudied [31,32].

88 To better understand the influence of arsenic on immune responses in pregnant women 89 and newborns, we established the Pregnancy, Arsenic, and Immune Response (PAIR) Study, a 90 longitudinal pregnancy and birth cohort, in rural northern Bangladesh. The PAIR Study was 91 designed to assess whether arsenic exposure and micronutrient deficiencies alter maternal or 92 newborn immunity and acute morbidity following maternal seasonal influenza vaccination during 93 pregnancy. We hypothesized that arsenic exposure and one-carbon metabolism micronutrient 94 deficiencies may alter maternal and newborn influenza antibody titer and avidity, measures of 95 systemic immune responses, and respiratory and other acute morbidity outcomes among 96 pregnant women and newborns.

97

98 COHORT DESCRIPTION

99 Study Area

100 The PAIR Study is based at the JiVitA Maternal and Child Health and Nutrition Research 101 Project (JiVitA) in rural northern Bangladesh. Approximately 45 million people in Bangladesh are 102 exposed to arsenic concentrations in drinking water >10 μ g/L (the WHO guideline value) and, of 103 these, approximately 20 million people are exposed to arsenic concentrations >50 µg/L (the 104 Bangladesh national standard) [33]. For nearly two decades, JiVitA has been one of the largest 105 research project sites in South Asia, covering ~650,000 people over 450 km² of Bangladesh's 106 Gaibandha and Rangpur Districts (Figure 1) [34]. JiVitA is an extensive field organization that 107 has conducted large trials of food and micronutrient supplements among pregnant women and 108 children [35–37]. A case-control study nested in a previous JiVitA micronutrient supplement trial 109 found that urinary arsenic was associated with seroconversion to hepatitis E virus between the 110 first trimester and three months postpartum among pregnant women in the study area [9]. The 111 PAIR Study builds on this work.

112

113 Enrollment and Vaccination

From July 2018 to February 2019, we conducted pregnancy surveillance to identify eligible pregnant women in the study area. A married woman of reproductive age (13-45 years) was eligible for the PAIR Study if she was pregnant and 13-14 weeks of gestational age (GW) (later 13-16 GW; see below), had no pre-existing immunodeficiency or chronic infection, had no previous or current use of immune-altering drugs or therapies (*e.g.*, steroids), and had not yet received an influenza vaccine for the 2018-19 influenza season.

120 The full JiVitA study area is divided into 566 sectors of ~150-300 households each (Figure 121 1). For the PAIR Study, surveillance began in 175 sectors closest to clinical centers where 122 vaccination and biospecimen collections, including venipuncture, could be safely performed and 123 samples could be uniformly processed ("PAIR Original Area" in Figure 1). We estimated a priori 124 that enrolling 850 pregnant women in 13-14 GW would yield a target sample size of 400 mother-125 infant pairs retained in the study to three months postpartum. We also determined a priori that 126 enrollment should end by March 2019 so that pregnancies would be limited to a single influenza 127 season and follow-up visits at 28 days post-vaccination would occur before the Ramadan fast 128 (May 5 to June 3, 2019). In November 2018, seeking to achieve the target enrollment in this time 129 window, we enlarged the study area by 163 sectors ("PAIR Extension Areas" in Figure 1) and 130 expanded eligibility criteria to 13-16 GW.

131 A total of 66,055 married women of reproductive age living in the original or extension 132 areas were identified by an earlier census or during pregnancy surveillance (Figure 2). During 133 surveillance, a female community health research worker (CHRW) visited each household every 134 four weeks and asked each married woman of reproductive age about the date of her last 135 menstrual period. If the date was >30 days prior to the visit, the woman was offered a urine 136 pregnancy test. A positive test indicated that the woman was pregnant. Gestational age was 137 calculated from the date of her last menstrual period. We completed at least one surveillance visit 138 to 46,775 women to identify 2,615 pregnant women (Figure 2). Of these, 845 women were eligible 139 and consented to enrollment, and 784 women enrolled in the PAIR Study between October 2018

140 and March 2019 (Figure 2). At enrollment, women received a quadrivalent seasonal inactivated influenza vaccine (VaxigripTetra, Sanofi Pasteur, Lyon, France), which was recommended by the 141 142 WHO for the 2018-19 Northern Hemisphere influenza season. We enrolled and administered the 143 vaccine to 8 women in GW 11-12, 775 women in GW 13-16, and 1 woman in GW 17. All vaccines 144 were maintained under a cold-chain protocol, carefully temperature-monitored, and administered 145 by trained nurses working under the supervision of a JiVitA physician. The vaccine contained four 146 inactivated influenza virus strains: A/Michigan/2015 (H1N1), A/Singapore/2016 (H3N2), 147 B/Maryland/2016, and B/Phuket/2013 [38].

148 Sociodemographic characteristics, including age, education, socioeconomic status, 149 household size (number of people), and house size (number of rooms excluding the kitchen and 150 storerooms), were similar between pregnant women who enrolled (n=784) and pregnant women 151 who did not enroll in the PAIR Study (n=1,519, after excluding women who were missing 152 sociodemographic information [n=313]) (**Table 1**). Women who enrolled tended to be younger 153 and have higher socioeconomic status, but the differences were small (Table 1). Socioeconomic 154 status was assessed by living standards index, which was generated by a principal components 155 analysis of household assets and home construction materials and validated in a previous JiVitA 156 study [39]. The use of tube wells to obtain groundwater for drinking and cooking was nearly 157 universal among enrollees (99.4%) and non-enrollees (99.8%) alike (Table 1).

158 **Table 1. Sociodemographic characteristics [n (%)] of pregnant women in the study area by**

159 enrollment in the Pregnancy, Arsenic, and Immune Response (PAIR) Study, Gaibandha

160 District, Bangladesh, 2018-2019.

	Enrolled	Not Enrolled*	
	(n=784)	(n=1,519)	р
Age (years)**			
<20	89 (11.4)	175 (11.5)	<0.01
20 to 29	499 (63.6)	859 (56.6)	
≥30	194 (24.7)	479 (31.5)	
Missing	2 (0.3)	6 (0.4)	
Maternal Education			
None	92 (11.7)	212 (14.0)	0.14
Class 1 to 9	548 (69.9)	1,065 (70.1)	
Class ≥10	144 (18.4)	240 (15.8)	
Missing	0 (0)	2 (0.1)	
Living Standards Index			
<median< td=""><td>360 (45.9)</td><td>792 (52.1)</td><td><0.01</td></median<>	360 (45.9)	792 (52.1)	<0.01
≥Median	424 (54.1)	727 (47.9)	
Household Size (people)			
2 to 3	307 (39.2)	518 (34.1)	0.05
4 to 5	336 (42.9)	720 (47.4%)	
≥6	139 (17.7)	277 (18.2)	
Missing	2 (0.3)	4 (0.3)	
House Size (rooms)***			
0 to 1	366 (46.7)	721 (47.5)	0.93
2 to 3	367 (46.8)	699 (46.0)	
≥4	51 (6.5)	98 (6.5)	
Missing	0 (0)	1 (0.1)	
Drinking Water Source			
Tube Well	779 (99.4)	1,516 (99.8)	-
Other	5 (0.6)	3 (0.2)	

161

Notes: All p values were calculated using χ^2 tests. A p value for Drinking Water Source was omitted because the number of people in the "Other" category was too small. *The table does not include non-enrolled women who did not complete a separate visit to assess sociodemographic variables (n=313). **Age as of July 2018 (start of pregnancy surveillance). ***Number of rooms excluding kitchen and storerooms.

167 Follow-up

168 <u>Study Visits</u>

169 In-person Visits

170 We completed up to 13 in-person visits to implement questionnaires and collect biological and 171 environmental specimens, beginning at enrollment and continuing to three months postpartum, 172 for a follow-up period of roughly 10-11 months, depending on the timing and duration of each 173 pregnancy (**Tables 2 and 3**). These included up to eight visits to the woman during pregnancy 174 and up to five visits to mother-infant pairs after live birth. At three visits (enrollment and 175 vaccination, 28 days post-vaccination, and three months postpartum), the CHRW brought 176 participants (the mother in pregnancy, the mother-infant pair after live birth) to a local clinical 177 center for detailed questionnaire and biospecimen collection. To minimize burden on mothers and 178 infants in the neonatal period, two home visits were conducted shortly after any live birth and 179 again within the first month postpartum for further questionnaire and biospecimen collection. Of 180 784 women who enrolled, 744 (94.9%) completed the 28-day post-vaccination visit, 598 (76.3%) 181 completed a visit within the first month postpartum, and 551 (70.3%) completed the three-month 182 postpartum visit (Table 4). In total, 736 (93.9%) enrolled women had 750 live births. Age, 183 gestational age, parity, education, living standards index, household size (number of people), 184 house size (number of rooms), height (cm), body mass index (kg/m²), and urinary arsenic were 185 similar among the women who enrolled and the subset of women who completed follow-up at 186 three months postpartum (Table 4).

187

188 Weekly Telephone Surveillance

In partnership with the Institute of Epidemiology Disease Control and Research (IEDCR), a unit of the Bangladesh Ministry of Health and Family Welfare, we conducted weekly telephone surveillance to ascertain acute morbidities in women (enrollment to three months postpartum) and infants (birth to three months of age). In women, we ascertained high fever with cough, high fever

193 with sore throat, diarrhea, vomiting, and abdominal pain. If a woman reported high fever with 194 cough or sore throat, she was asked further if she had congestion, headache, or chills at the same 195 time. In infants, we ascertained high fever with cough, diarrhea, and vomiting. If a woman reported 196 that her infant had high fever with cough, she was asked further if the infant had congestion or 197 shortness of breath at the same time. Of 784 women enrolled in the PAIR Study and 750 infants 198 born to them, 743 women (94.8%) and 628 infants (83.7%) participated in the surveillance. While 199 weekly telephone surveillance was prespecified to end at three months postpartum, for some 200 women and infants it continued for longer. The median (interguartile range [IQR]) number of 201 weeks with complete calls was 35 (23-42) for women and 17 (12-22) for infants.

202

203 Environmental Specimens

204 We collected a water specimen from the tube well that each participant indicated was her primary 205 source of drinking water before each center visit and at the home visit conducted within one month 206 postpartum (Table 2). Just prior to collection, the well was flushed for approximately five minutes. 207 Specimens were collected into conical vials certified by the manufacturer as trace-metal free (<1 208 µg/L for 20 metals, including As), and transported to the local JiVitA lab at 4-10°C. Specimens 209 were aliquoted and stored at -20°C prior to analysis. Tube well water specimens were analyzed 210 for total arsenic (wAs) and other elements (Al, Ba, Br, Ca, Cd, Cu, Fe, K, Mg, Mn, Mo, Na, P, Pb, 211 S, Sb, Si, Sr, U, V, W, Zn) at the Lamont-Doherty Earth Observatory in Palisades, NY using 212 inductively coupled plasma mass spectrometry [40]. Empty trace metal-free conical vials and 213 aliquot tubes were assessed as blanks. The LOD for wAs was 0.02 µg/L.

214

215 <u>Biological Specimens</u>

Up to 22 mL of venous blood was collected from mothers at each of the three center visits:
enrollment/vaccination, 28 days post-vaccination, and three months postpartum (**Table 2**). Up to
1 mL of capillary blood was collected from infants by heel stick during the center visit at three

219 months postpartum (Table 3). At the home visit within approximately one month of live birth, blood 220 was collected from mothers and infants using the methods described for the center visits. Blood 221 specimens were transported in temperature-controlled and -monitored coolers to a JiVitA 222 laboratory. Laboratory technicians processed maternal blood to serum, plasma, and peripheral 223 blood mononuclear cells (PBMCs), and processed infant blood to serum, on the day of collection. 224 Serum and plasma were frozen and maintained at -80°C. PBMCs were cryopreserved following 225 established protocols [41]. Serum and plasma were shipped on dry ice, and PBMCs were shipped 226 in vapor phase liquid nitrogen canisters, to the Johns Hopkins University in Baltimore, Maryland. 227 Maternal and infant sera were tested for antibody for the influenza vaccine antigens by 228 hemagglutination-inhibition (HAI) assay at Sanofi Pasteur in Swiftwater, Pennsylvania [42]. We 229 also will determine avidity of IgG antibodies specific to the influenza vaccine antigens; serum 230 cytokine and chemokine concentrations as measures of immune function; immune cell population 231 characterization; and T-cell stimulation assays using the influenza vaccine antigens. 232 Micronutrients relevant to one-carbon metabolism will be measured in maternal plasma.

233 Urine was collected from all mothers at the three center visits and during the home visit 234 within one month of birth, and from a subset of mothers (n=468) during a home visit in late 235 pregnancy (Table 2). Mothers were asked to provide a urine specimen in a collection cup. A 236 CHRW immediately transferred the specimen to a container certified by the manufacturer as 237 trace-metal free (<1 µg/L for 20 metals, including As) and the specimens were transported to the 238 JiVitA laboratory. Urine specimens were aliquoted and stored at -20°C prior to analysis. Urinary 239 elements (Al, Ba, Br, Ca, Cd, Cs, Cu, Fe, K, Li, Mg, Mn, Mo, Na, P, Pb, Rb, S, Sb, Se, Si, Sr, U, 240 V, W, Zn) were measured at the Institute of Chemistry - Analytical Chemistry at the University of 241 Graz in Graz, Austria using inductively coupled plasma tandem mass spectrometry (ICP-MS/MS). 242 Urinary arsenic was speciated (arsenite, arsenate, monomethylarsonic acid (MMA), 243 dimethylarsinic acid (DMA), and arsenobetaine and other cations) by high performance liquid 244 chromatography (HPLC) with ICP-MS/MS as described by Scheer et al. [43]. Empty trace-metal

free containers and aliquot tubes were assessed as blanks. The limits of detection (LODs) for arsenic species were 0.05 μ g/L. To assess arsenic exposure, we summed urinary inorganic arsenic (the sum of arsenite and arsenate; iAs), MMA, and DMA (Σ uAs) [44]. To assess arsenic metabolism, we calculated proportions of urinary iAs, MMA, and DMA, relative to Σ uAs, and reported them as iAs%, MMA%, and DMA% [22]. All urinary concentrations were corrected for specific gravity measured by refractometric determination of total solids.

251 We collected oral fluid, which includes saliva, oral mucosal transudate from the capillary 252 bed, and crevicular fluid, from mothers at each center visit, the home visit after birth, and additional 253 monthly home visits, and from infants in all visits beginning at one month postpartum (Tables 2 254 and 3). Crevicular fluid, which flows between the gums and the teeth, is rich in antibodies and 255 reflects the IgG profile of the serum. Oral fluid was collected by brushing the gum line with an 256 oral-mucosal transudate collection swab [45-47]. Microsphere magnetic bead-based assays will 257 be applied to measure IgG and IgA responses specific to the influenza vaccine strains as well as 258 a variety of endemic respiratory and gastrointestinal pathogens [45,46,48].

259 If a mother reported influenza-like illness (ILI) in herself or her infant during weekly 260 surveillance, a CHRW aimed to conduct a home visit and collect a nasal swab within 24 hours of 261 the call (Tables 2 and 3). ILI was defined as high fever with cough or sore throat in women and 262 high fever with cough in infants [49]. Severity was determined by calculating the sum of acute 263 morbidity symptoms reported during surveillance. Given limited capacity, women or infants with 264 the highest sum score were prioritized for the collection of a nasal swab. After collection by a 265 CHRW, swabs were placed in universal transport medium. The transport medium was intended 266 for the preservation of viruses (Puritan UniTranz-RT, Guilford, ME, USA). Samples were 267 transported to the local JiVitA lab and stored at -80°C. Nasal swabs were periodically batch-268 transported to IEDCR in Dhaka, Bangladesh, in liquid nitrogen, where RNA will be extracted and 269 tested by RT-qPCR for influenza A and B virus, including sub-types, according to WHO protocols 270 to assess laboratory-confirmed ILI [50].

271

272 <u>Anthropometry</u>

Maternal weight (kg), height (cm), mid-upper arm circumference (MUAC) (cm), and triceps and subscapular skinfolds (mm) were measured at enrollment/vaccination and three months postpartum (**Table 2**) [36,43,52]. Maternal weight was also measured at 28 days post-vaccination, late pregnancy, and one-month postpartum. Maternal MUAC was also measured at late pregnancy and one-month postpartum. Infant weight, MUAC, chest circumference, head circumference, and length were recorded at the birth assessment visit (**Table 3**) [36,43,52]. Infant growth was monitored by repeating these measurements at one- and three-months postpartum.

280

281 <u>Vitals</u>

282 Blood pressure, hemoglobin, and body temperature of mothers were measured by a local nurse 283 each time a mother had blood drawn (**Table 2**). Systolic and diastolic blood pressure were 284 measured twice, in the left arm, with the woman in a relaxed and seated position using a 285 WelchAllyn DuraShock DS66 Trigger Aneroid Sphygmomanometer (Skaneateles Falls, New 286 York, USA). Hemoglobin was measured in capillary blood by real-time assay using a HemoCue 287 Hb 301 analyzer (Ängelholm, Sweden). Body temperature of infants was measured at the birth 288 assessment and three months postpartum, and hemoglobin was measured at three months 289 postpartum by a local nurse (**Table 3**). Vitals were recorded and provided to the mother after each 290 collection. Pregnant women and infants who were severely anemic (hemoglobin <7 g/dL)[53] 291 were given iron tablets and iron syrup, respectively, consistent with the study protocol and as 292 approved by the IRB. Blood type was determined using anti-A, anti-B, and anti-D blood grouping 293 reagents (Cromatest, LiNEAR, Montgat, Spain).

294

295 Questionnaires

296 Questionnaires conducted at multiple visits between enrollment/vaccination and three months 297 postpartum covered a variety of topics (Table 2), including questions related to the intentionality 298 of pregnancy, seven- and thirty-day morbidity including influenza-like illness, seven-day food 299 frequency, mental health, seven-day strenuous work activity, six-month pesticide storage and 300 use, poultry farming and exposures, handwashing practices, tobacco use and smoke exposure, 301 medical and vaccination history, household food security, and more. Additional guestionnaires 302 asked about the birth and delivery of infants, including characteristics of labor and delivery, 303 micronutrient supplement consumption, and health crisis events. Answers to questionnaires for 304 infants were most often provided by the mother, and included morbidity, breastfeeding practices, 305 early feeding practices, infant injury and bleeding, immunization and supplementation, and 306 hospitalization history and medication use (**Table 3**). Topics related to arsenic exposure included 307 drinking water, rice products, and tobacco products and smoke exposure in the previous week.

308

309 Patient and Public Involvement

JiVitA was established and operates in consultation with local community stakeholders, many of whom are hired as JiVitA staff. JiVitA has benefited from their continued support for nearly two decades. Participants were not directly involved in the design of the PAIR Study.

313 Table 2. Measurements collected in pregnant women in the Pregnancy, Arsenic, and Immune Response (PAIR) Study,

	Gestation							Postpartum					Both	
Visit	0	1	2	3	4	5	6	7	8	9	10	11	12	
Biological Samples														
Serum	Х	Х								Х			Х	
Plasma	Х	Х								Х			Х	
PBMCs	Х	Х								Х			Х	
Urine	Х	Х						X**		Х			Х	
Oral fluid	Х	Х	Х	Х	Х	Х	Х			Х	Х	Х	Х	
Nasal swab														X***
Environmental Samples														
Tube well water	Х	Х								Х			Х	
Anthropometry														
Weight	Х	Х						Х			Х		Х	
Height	Х												Х	
Mid-upper arm circumference	Х							Х			Х		Х	
Triceps skinfold	Х												Х	
Subscapular skinfold	Х												Х	
Vitals														
Blood pressure	Х	Х								Х			Х	
Body temperature	Х	Х								Х			Х	
Hemoglobin	Х	Х								Х			Х	
Blood typing	Х													
Questionnaires														
Intentionality of pregnancy	Х													
7- or 30-day morbidity	Х	Х	Х	Х	Х	Х	Х	Х		Х	Х	Х	Х	Х
7-day food frequency	Х							Х					Х	
Rice and water consumption	Х	Х						Х		Х			Х	
Mental health	Х							Х					Х	
7-day strenuous work activity	Х							Х					Х	
Pesticide exposure history	Х												Х	
Poultry handling and exposure	X												Х	

314 Gaibandha District, Bangladesh, 2018-2019.

Handwashing and latrine use	Х						Х	
Tobacco use and exposure	Х			Х			Х	
Medical history	Х							
Vaccination history	Х							
Household food security	Х						Х	
Tube well usage	Х	Х					Х	
Altered food consumption				Х				
Planned location of delivery				Х				
Date and time of birth					Х			
Labor and delivery					Х			
Micronutrient supplements						Х		
Health crisis events						Х		
Resumption of menstruation							Х	
Vaccination since enrollment							Х	

315

Notes: Visit 0 = enrollment/vaccination, Visit 1 = 28 days post-vaccination, Visit 8 = birth assessment, Visit 9 = first month of life, Visit
 12 = three months post-partum, PBMCs = peripheral blood mononuclear cells. * Timing of visit varied depending on pregnancy timing

318 and duration. ** Urine collected in a subset of women. *** A nasal swab was collected if symptoms defining influenza-like illness were

319 reported during weekly telephone surveillance, based on severity.

320 Table 3. Measurements collected in infants in the Pregnancy, Arsenic, and Immune

	Postp	artum				Both
Visit	8	9	10	11	12	
Biological Samples						
Serum		Х			Х	
Oral fluid			Х	Х	Х	
Nasal swab						X*
Anthropometry						
Weight	Х		Х		Х	
Length	Х		Х		Х	
Mid-upper arm circumference	Х		Х		Х	
Chest circumference	Х		Х		Х	
Head circumference	Х		Х		Х	
Vitals						
Body temperature		Х			Х	
Hemoglobin					Х	
Blood typing					Х	
Questionnaires						
Date and time of birth	Х					
Birth outcome	Х					
Condition of infant at birth	Х					
Newborn care practices	Х					
7-day morbidity		Х	Х	Х	Х	Х
Morbidities in first 28 days			Х			
Breastfeeding practices			Х		Х	
Early feeding			Х			
Injury and bleeding			Х			
Two-month morbidity	Х					
Child's diet	Х					

321 Response (PAIR) Study, Gaibandha District, Bangladesh, 2018-2019.

322

323 Notes: Visit 8 = birth assessment, Visit 9 = first month of life, Visit 12 = three months post-partum.

Х

Х

Х

Х

Х

324 * A nasal swab was collected if symptoms defining influenza-like illness were reported during

325 weekly telephone surveillance, based on severity.

Immunization history

Bleeding disorders

Recent medication

Hospitalization history

Vitamin A supplementation

- 326 Table 4. Sociodemographic characteristics [n (%)] of pregnant women at enrollment in the
- 327 Pregnancy, Arsenic, and Immune Response (PAIR) Study, Gaibandha District,
- 328 Bangladesh, 2018-2019, by completion of major study visits.

	Farellasent	28 Days Post-	First Month	Three Months
	Enrollment	vaccination	of Life	Post-partum
Completed	784 (100)	744 (94.9)	598 (76.3)	551 (70.3)
Maternal Age (years)*				
<20	77 (9.8)	73 (9.8)	61 (10.2)	53 (9.6)
20 to 29	488 (62.2)	464 (62.4)	375 (62.7)	345 (62.6)
≥30	217 (27.7)	205 (27.6)	160 (26.8)	151 (27.4)
Missing	2 (0.3)	2 (0.3)	2 (0.3)	2 (0.4)
Gestational Age (weeks)				
11 to 13	306 (39.0)	284 (38.2)	227 (38.0)	204 (37.0)
14	250 (31.9)	242 (32.5)	198 (33.1)	186 (33.8)
15	104 (13.3)	101 (13.6)	80 (13.4)	73 (13.2)
16 to 17	124 (15.8)	117 (15.7)	93 (15.6)	88 (16.0)
Parity				
Nulliparous	140 (17.9)	136 (18.3)	107 (17.9)	90 (16.3)
Primiparous	364 (46.4)	340 (45.7)	278 (46.5)	262 (47.6)
Multiparous	280 (35.7)	268 (36.0)	213 (35.6)	199 (36.1)
Maternal Education				
None	92 (11.7)	89 (12.0)	60 (10.0)	57 (10.3)
Class 1 to 9	548 (69.9)	521 (70.0)	431 (72.1)	396 (71.9)
Class ≥10	144 (18.4)	134 (18.0)	107 (17.9)	98 (17.8)
Living Standards Index				
<median< td=""><td>392 (50.0)</td><td>370 (49.7)</td><td>294 (49.2)</td><td>272 (49.4)</td></median<>	392 (50.0)	370 (49.7)	294 (49.2)	272 (49.4)
≥Median	392 (50.0)	374 (50.3)	304 (50.8)	279 (50.6)
Household Size (people)				
2 to 3	307 (39.2)	289 (38.8)	224 (37.5)	207 (37.6)
4 to 5	336 (42.9)	321 (43.1)	259 (43.3)	238 (43.2)
≥6	139 (17.7)	132 (17.7)	113 (18.9)	104 (18.9)
Missing	2 (0.3)	2 (0.3)	2 (0.3)	2 (0.4)
House Size (rooms)				
0 to 1	366 (46.7)	342 (46.0)	268 (44.8)	248 (45.0)
2 to 3	367 (46.8)	353 (47.4)	294 (49.2)	270 (49.0)
≥4	51 (6.5)	49 (6.6)	36 (6.0)	33 (6.0)
Height (cm)				
Mean (SD)	150 (5.20)	150 (5.19)	150 (5.17)	150 (5.19)
Body Mass Index (kg/m ²)				
Mean (SD)	21.9 (3.44)	22.0 (3.41)	21.9 (3.36)	22.0 (3.36)
Urine Arsenic (∑uAs) (μg/L)**				
Tertile 1 (2.98 to 22.5)	261 (33.3)	250 (33.6)	203 (33.9)	189 (34.3)
Tertile 2 (22.5 to 45.6)	261 (33.3)	248 (33.3)	193 (32.3)	175 (31.8)
Tertile 3 (46.3 to 451)	261 (33.3)	245 (32.9)	201 (33.6)	186 (33.8)
Missing	1 (0.1)	1 (0.1)	1 (0.2)	1 (0.2)

329 * Age at enrollment. ** Urinary arsenic is the sum if inorganic and methylated arsenic species.
330

331 FINDINGS TO DATE

332 Water arsenic was ≥0.02 µg/L in 97.9% of drinking water specimens collected from participants' 333 tube wells on the day of enrollment. The median (IQR) of wAs was 5.1 (0.5-25.1) µg/L (Figure 3) 334 with 39.4% of samples above the WHO guideline value of 10 µg/L and 13.2% above the 335 Bangladesh national standard of 50 µg/L. wAs appears to be lower in the study area than in other 336 regions of Bangladesh where epidemiologic studies have been conducted [54,55]. Urinary iAs, 337 MMA, and DMA were ≥LOD in all specimens collected at enrollment. The median (IQR) of their 338 sum, $\sum uAs$, was 33.1 (19.6-56.5) $\mu g/L$ (Figure 3). Urinary arsenobetaine (and other unretained 339 arsenic species) levels were low (median: 0.8 µg/L, IQR: 0.4-1.7 µg/L), suggesting low exposure 340 to organic arsenic from seafood in the population [56]. \sum uAs was strongly correlated with wAs in 341 participants with wAs \geq median (Spearman's ρ =0.72) but weakly correlated with wAs in 342 participants with wAs < median (Spearman's ρ =0.18) (**Figure 4**). This suggests that, at lower concentrations of wAs, other sources of arsenic (e.g., other tube wells, rice) contribute relatively 343 344 more to exposure [57]. SuAs and wAs will provide complementary approaches to exposure 345 assessment. SuAs integrates exposures from multiple sources, including drinking water and diet, 346 but has a short biological half-life and may over- or under-estimate long-term exposure [44]. By 347 contrast, wAs reflects a single source of exposure but is more stable over time. Future work will 348 characterize exposure to arsenic and other metals and associations with health outcomes, 349 including maternal antibody response to influenza vaccination, transplacental transfer of maternal 350 antibodies, and respiratory morbidity, as well as interactions between arsenic exposure and 351 micronutrient deficiencies in these outcomes.

352

353 STRENGTHS AND LIMITATIONS

Strengths of the PAIR Study include a large, representative sample of pregnant women and 354 355 infants in rural northern Bangladesh. The women received the same seasonal influenza vaccine 356 at approximately the same time during pregnancy and during the same influenza season. This 357 design will enable us to assess whether arsenic exposure is associated with antibody responses 358 to seasonal influenza vaccination in pregnant women or transplacental transfer of maternal 359 antibodies to the fetus while avoiding potential confounders related to stage of pregnancy and 360 annual variability in influenza viruses. Because wAs appears to be lower in the PAIR Study than 361 in other epidemiologic studies in Bangladesh, we can assess whether low-moderate arsenic 362 exposure is associated with relevant maternal and infant outcomes. Biological and environmental 363 specimens provide objective measures of arsenic exposure and immune and respiratory and 364 other acute morbidity outcomes. Weekly telephone surveillance provides ascertainment of ILI 365 symptoms and real-time PCR testing of ILI-symptomatic event anterior nasal swabs provides 366 time-resolved information on maternal and infant laboratory-confirmed influenza A/B infection. 367 Limitations include occasional delays in study visits. While JiVitA possesses an extensive field 368 organization, logistical barriers to conducting frequent home visits over a large study area 369 prevented some study visits from occurring as scheduled. Additionally, it was not logistically 370 feasible to collect umbilical cord blood specimens to assess transplacental transfer of maternal 371 antibodies. However, infant-to-maternal HAI antibody titer ratios measured in serum during the 372 first month of life should provide a reasonable alternative because neonates demonstrate only a 373 limited adaptive immune response that would allow them to generate IgG antibodies 374 independently [58], and the maternal antibodies received through breastfeeding are IgA.

375

376 COLLABORATION

The PAIR Study was designed and conducted through collaboration among investigators at the
Johns Hopkins University, Columbia University, and the University of North Carolina at Chapel
Hill in the United States; the University of Graz in Austria; and the JiVitA Maternal and Child Health

- 380 and Nutrition Research Project in Bangladesh. We welcome further collaboration. Please contact
- the principal investigators, Dr. Christopher D. Heaney [cheaney1@jhu.edu] and Dr. Alain B.
- 382 Labrique [alabriq1@jhu.edu], for more information.

383 FURTHER DETAILS

384 <u>Contributions</u>

385 LNA and TJSS contributed equally to this paper. LNA: Writing – Original Draft, Data Curation, 386 Methodology, Visualization; **TJSS**: Writing – Original Draft, Data Curation, Formal Analysis, 387 Software, Visualization; ANA: Writing – Review & Editing, Conceptualization, Methodology, 388 Supervision; **KK**: Data Curation, Resources; **NP**: Writing – Review & Editing, Conceptualization, 389 Data Curation, Methodology, Project Administration; PRR: Methodology, Project Administration; 390 **B Detrick:** Writing – Review & Editing, Conceptualization, Methodology; **RCF:** Writing – Review 391 & Editing, Conceptualization, Methodology; AvG: Writing - Review & Editing, Investigation, 392 Methodology; WG: Writing – Review & Editing, Investigation, Methodology; RAK: Writing – 393 Review & Editing, Conceptualization, Methodology; SLK: Writing – Review & Editing, 394 Conceptualization, Methodology; ELO: Methodology; MWK: Conceptualization, Methodology, 395 Resources: **K Alland:** Writing – Review & Editing. Conceptualization. Methodology. Supervision: 396 K Ayesha: Investigation, Supervision; B Dyer: Data Curation, Software; MTI: Investigation, 397 Methodology; HAO: Investigation, Project Administration; MHR: Investigation, Methodology, 398 Supervision; HA: Investigation, Methodology, Project Administration, Supervision; RH: Data 399 Curation, Methodology, Supervision; **SS:** Conceptualization, Methodology, Project 400 Administration, Supervision; KJS: Writing – Review & Editing, Conceptualization; AKMM: 401 Investigation, Methodology; ASMA: Conceptualization, Methodology, Supervision; MSF: 402 Methodology, Supervision; KPW: Conceptualization, Funding Acquisition, Supervision; ABL: 403 Conceptualization, Funding Acquisition, Investigation, Methodology, Project Administration, 404 Supervision; CDH: Writing - Review & Editing, Conceptualization, Data Curation, Funding 405 Acquisition, Investigation, Methodology, Project Administration, Resources, Supervision.

406

407 Funding

408 The PAIR study was supported by the National Institute of Environmental Health Sciences 409 (NIEHS; R01ES026973) and by an unrestricted grant from Sanofi Pasteur, Lyon, France, which 410 also provided the study vaccine and vaccine antibody testing. PAIR also benefited from common 411 JiVitA infrastructure and staff supported by the UBS Optimus Foundation and the Bill & Melinda 412 Gates Foundation. LNA was supported by a grant from the U.S. Centers for Disease Control and 413 Prevention, National Institute for Occupational Safety and Health to the Johns Hopkins Education 414 and Research Center for Occupational Safety and Health (T42 OH0008428) and the National 415 Science Foundation Graduate Research Fellowship (DGE-1746891). TJSS was supported by 416 NIEHS (T32ES007141).

417

418 Competing Interests

- 419 The authors declare they have no competing interests.
- 420

421 Ethics Approval

This study was approved by the institutional review boards of the Johns Hopkins Bloomberg School of Public Health (00008247) and the Institute of Epidemiology, Disease Control and Research (IEDCR/IRB/2017/07). All participants gave informed consent prior to enrollment.

425 **REFERENCES**

- 426 1 Ravenscroth P, Brammer H, Richards K. *Arsenic Pollution: A Global Synthesis*. West
 427 Sussex: Wiley-Blackwell 2009. doi:10.1002/9781444308785
- 428 2 International Agency for Research on Cancer (IARC). *Arsenic and Arsenic Compounds*.
 429 Geneva: World Health Organization 2012.
- Moon KA, Oberoi S, Barchowsky A, *et al.* A dose-response meta-analysis of chronic
 arsenic exposure and incident cardiovascular disease. *Int J Epidemiol* 2017;**46**:1924–39.
 doi:10.1093/ije/dyx202
- 433 4 Navas-Acien A, Spratlen MJ, Abuawad A, *et al.* Early-Life Arsenic Exposure, Nutritional
 434 Status, and Adult Diabetes Risk. *Curr Diab Rep* 2019;**19**:147–54. doi:10.1007/s11892-019435 1272-9
- Ahmed S, Moore SE, Kippler M, *et al.* Arsenic exposure and cell-mediated immunity in preschool children in rural Bangladesh. *Toxicol Sci* 2014;**141**:166–75.
 doi:10.1093/toxsci/kfu113
- Welch BM, Branscum A, Geldhof GJ, *et al.* Evaluating the effects between metal mixtures
 and serum vaccine antibody concentrations in children: A prospective birth cohort study. *Environ Health* 2020;**19**:41. doi:10.1186/s12940-020-00592-z
- Welch BM, Branscum A, Ahmed SM, *et al.* Arsenic exposure and serum antibody
 concentrations to diphtheria and tetanus toxoid in children at age 5: A prospective birth
 cohort in Bangladesh. *Environ Int* 2019;**127**:810–8. doi:10.1016/j.envint.2019.04.015
- Raqib R, Ahmed S, Ahsan K bin, *et al.* Humoral immunity in arsenic-exposed children in
 rural Bangladesh: Total immunoglobulins and vaccine-specific antibodies. *Environ Health Perspect* 2017;**125**:067006. doi:10.1289/EHP318
- Heaney CD, Kmush B, Navas-Acien A, *et al.* Arsenic exposure and hepatitis E virus
 infection during pregnancy. *Environ Res* 2015;**142**:273–80.
 doi:10.1016/j.envres.2015.07.004

- 451 10 Kile ML, Rodrigues EG, Mazumdar M, *et al.* A prospective cohort study of the association 452 between drinking water arsenic exposure and self-reported maternal health symptoms
- 453 during pregnancy in Bangladesh. *Environ Health* 2014;**13**. doi:10.1186/1476-069X-13-29
- Smith AH, Marshall G, Yuan Y, *et al.* Evidence from Chile that arsenic in drinking water
 may increase mortality from pulmonary tuberculosis. *Am J Epidemiol* 2011;**173**:414–20.
- 456 doi:10.1093/aje/kwq383
- 457 12 Smith AH, Marshall G, Yuan Y, *et al.* Increased mortality from lung cancer and
 458 bronchiectasis in young adults after exposure to arsenic in utero and in early childhood.
 459 *Environ Health Perspect* 2006;**114**:1293–6. doi:10.1289/ehp.8832
- Attreed SE, Navas-Acien A, Heaney CD. Arsenic and Immune Response to Infection
 During Pregnancy and Early Life. *Cur Environ Health Rep* 2017;**4**:229–43.
 doi:10.1007/s40572-017-0141-4
- 463 14 Islam LN, Nabi AHMN, Rahman MM, et al. Association of respiratory complications and 464 elevated serum immunoglobulins with drinking water arsenic toxicity in human. J Environ 465 Subst Sci Health Α Tox Hazard Environ Eng 2007;**42**:1807–14. 466 doi:10.1080/10934520701566777
- Farzan SF, Korrick S, Li Z, *et al.* In utero arsenic exposure and infant infection in a United
 States cohort: a prospective study. *Environ Res* 2013;**126**:24–30.
 doi:10.1016/j.envres.2013.05.001
- 470 16 Farzan SF, Li Z, Korrick SA, *et al.* Infant Infections and Respiratory Symptoms in Relation
 471 to in Utero Arsenic Exposure in a U.S. Cohort. *Environ Health Perspect* 2016;**124**:840–7.
 472 doi:10.1289/ehp.1409282
- 473 17 Ahmed SM, Branscum A, Welch BM, *et al.* A prospective cohort study of in utero and early
 474 childhood arsenic exposure and infectious disease in 4- to 5-year-old Bangladeshi children.
- 475 Environ Epidemiol 2020;**4**:e086. doi:10.1097/EE9.0000000000000086

- 476 18 George CM, Brooks WA, Graziano JH, *et al.* Arsenic exposure is associated with pediatric
 477 pneumonia in rural Bangladesh: a case control study. *Environ Health* 2015;**14**:83.
 478 doi:10.1186/s12940-015-0069-9
- Rahman A, Vahter M, Ekström E-C, *et al.* Arsenic exposure in pregnancy increases the
 risk of lower respiratory tract infection and diarrhea during infancy in Bangladesh. *Environ Health Perspect* 2011;**119**:719–24. doi:10.1289/ehp.1002265
- Raqib R, Ahmed S, Sultana R, *et al.* Effects of in utero arsenic exposure on child immunity
 and morbidity in rural Bangladesh. *Toxicol Lett* 2009;**185**:197–202.
 doi:10.1016/j.toxlet.2009.01.001
- Smith AH, Yunus M, Khan AF, *et al.* Chronic respiratory symptoms in children following in
 utero and early life exposure to arsenic in drinking water in Bangladesh. *Int J Epidemiol*2013;**42**:1077–86. doi:10.1093/ije/dyt120
- 488 22 Kuo CC, Moon KA, Wang SL, *et al.* The association of arsenic metabolism with cancer,
 489 cardiovascular disease, and diabetes: A systematic review of the epidemiological
 490 evidence. *Environ Health Perspect* 2017;**125**. doi:10.1289/EHP577
- 491 23 Hopenhayn C, Huang B, Christian J, *et al.* Profile of urinary arsenic metabolites during
 492 pregnancy. *Environ Health Perspect* 2003;**111**:1888–91. doi:10.1289/ehp.6254
- 493 24 Concha G, Vogler G, Lezcano D, *et al.* Exposure to inorganic arsenic metabolites during
 494 early human development. *Toxicol Sci* 1998;44:185–90. doi:10.1006/toxs.1998.2486
- 495 25 World Health Organization. WHO position paper on influenza vaccines November 2012.
 496 Weekly Epidemiological Record 2012;87:461–76.
- Zaman K, Roy E, Arifeen SE, *et al.* Effectiveness of maternal influenza immunization in
 mothers and infants. *New Engl J Med* 2008;**359**:1555–64. doi:10.1056/NEJMoa0708630
- 499 27 Reuman PD, Ayoub EM, Small PA. Effect of passive maternal antibody on influenza illness
- 500 in children: a prospective study of influenza A in mother-infant pairs. *Pediatr Infect Dis J*
- 501 1987;**6**:398–403. doi:10.1097/00006454-198704000-00011

- 502 28 Puck JM, Glezen WP, Frank AL, *et al.* Protection of infants from infection with influenza A
 503 virus by transplacentally acquired antibody. *J Infect Dis* 1980;**142**:844–9.
 504 doi:10.1093/infdis/142.6.844
- 505 29 Glezen WP, Taber LH, Frank AL, *et al.* Influenza virus infections in infants. *Pediatr Infect* 506 *Dis J* 1997;**16**:1065–8. doi:10.1097/00006454-199711000-00012
- Neuzil KM, Reed GW, Mitchel EF, *et al.* Impact of influenza on acute cardiopulmonary
 hospitalizations in pregnant women. *Am J Epidemiol* 1998;**148**:1094–102.
 doi:10.1093/oxfordjournals.aje.a009587
- 510 31 Ser PH, Banu B, Jebunnesa F, *et al.* Arsenic exposure increases maternal but not cord 511 serum IgG in Bangladesh. *Pediatr Int* 2015;**57**:119–25. doi:10.1111/ped.12396
- Attreed SE, Navas-Acien A, Heaney CD. Arsenic and Immune Response to Infection
 During Pregnancy and Early Life. *Curr Environ Health Rep* 2017;**4**:229–43.
 doi:10.1007/s40572-017-0141-4
- 515 33 Flanagan S v, Johnston RB, Zheng Y. Arsenic in tube well water in Bangladesh: health and
 516 economic impacts and implications for arsenic mitigation. *Bull World Health Organ*517 2012;**90**:839–46. doi:10.2471/BLT.11.101253
- Ali H, Hamadani J, Mehra S, *et al.* Effect of maternal antenatal and newborn
 supplementation with Vitamin A on cognitive development of school-aged children in rural
 Bangladesh: A follow-up of a placebo-controlled, randomized trial. *Am J Clin Nutr*2017;**106**:77–87. doi:10.3945/ajcn.116.134478
- 522 35 Klemm RDW, Labrique AB, Christian P, *et al.* Newborn Vitamin A Supplementation
 523 Reduced Infant Mortality in Rural Bangladesh. *Pediatrics* 2008;**122**:e242–50.
 524 doi:10.1542/peds.2007-3448
- 525 36 West Jr. KP, Christian P, Labrique AB, *et al.* Effects of vitamin A or beta carotene 526 supplementation on pregnancy-related mortality and infant mortality in rural Bangladesh: A 527 cluster randomized trial. *JAMA* 2011;**305**:1986–95. doi:10.1001/jama.2011.656

- West Jr. KP, Shamim AA, Mehra S, *et al.* Effect of Maternal Multiple Micronutrient vs IronFolic Acid Supplementation on Infant Mortality and Adverse Birth Outcomes in Rural
 Bangladesh: The JiVitA-3 Randomized Trial. *JAMA* 2014;**312**:2649–58.
 doi:10.1001/jama.2014.16819
- Serradell L, Wagué S, Moureau A, *et al.* Enhanced passive safety surveillance of a trivalent
 and a quadrivalent influenza vaccine in Denmark and Finland during the 2018/2019
 season. *Hum Vaccin Immunother* 2021;**17**:1205–10.
 doi:10.1080/21645515.2020.1804247
- 536 39 Gunnsteinsson S, Labrique AB, West KP, *et al.* Constructing indices of rural living
 537 standards in Northwestern Bangladesh. *J Health Popul Nutr* 2010;**28**:509–19.
 538 doi:10.3329/jhpn.v28i5.6160
- 539 40 Cheng Z, Zheng Y, Mortlock R, *et al.* Rapid multi-element analysis of groundwater by high540 resolution inductively coupled plasma mass spectrometry. *Anal Bioanal Chem*541 2004;**379**:512–8. doi:10.1007/s00216-004-2618-x
- 542 41 Weinberg A. Cryopreservation of Peripheral Blood Mononuclear Cells. In: Detrick B,
 543 Schmitz JL, Hamilton RG, eds. *Manual of Molecular and Clinical Laboratory Immunology*.
 544 Washington, DC: ASM Press 2016. 263–8.
- 545 42 Ohmit SE, Petrie JG, Cross RT, *et al.* Influenza hemagglutination-inhibition antibody titer 546 as a correlate of vaccine-induced protection. *J Infect Dis* 2011;**204**:1879–85. 547 doi:10.1093/infdis/jir661
- 548 43 Scheer J, Findenig S, Goessler W, *et al.* Arsenic species and selected metals in human
 549 urine: validation of HPLC/ICPMS and ICPMS procedures for a long-term population-based
 550 epidemiological study. *Anal Methods* 2012;**4**:406–13. doi:10.1039/C2AY05638K
- 551 44 National Research Council. *Arsenic in Drinking Water*. Washington, DC: : National
 552 Academies Press 1999. doi:10.17226/6444

- 553 45 McKie A, Vyse A, Maple C. Novel methods for the detection of microbial antibodies in oral 554 fluid. *Lancet Infect Dis* 2002;**2**:18–24. doi:10.1016/s1473-3099(01)00169-4
- 555 46 Randad PR, Hayford K, Baldwin R, *et al.* The Utility of Antibodies in Saliva to Measure
- 556 Pathogen Exposure and Infection. In: Granger Douglas A., Taylor Marcus K., eds. Salivary
- 557 Bioscience: Foundations of Interdisciplinary Saliva Research and Applications. Cham,
- 558 Switzerland: Springer Nature 2020. 287–319. doi:10.1007/978-3-030-35784-9
- 559 47 Brandtzaeg PER. Do salivary antibodies reliably reflect both mucosal and systemic 560 immunity? *Ann N Y Acad Sci* 2007;**1098**:288–311. doi:10.1196/annals.1384.012
- 561 48 Randad PR, Pisanic N, Kruczynski K, et al. COVID-19 serology at population scale: SARS-
- 562 CoV-2-specific antibody responses in saliva. *J Clin Microbiol* 2020;**59**:e02204. 563 doi:10.1128/JCM.02204-20
- Fitzner J, Qasmieh S, Mounts AW, *et al.* Revision of clinical case definitions: influenza-like
 illness and severe acute respiratory infection. *Bull World Health Organ* 2018;**96**:122–8.
 doi:10.2471/BLT.17.194514
- 567 50 World Health Organization (WHO). Information for the Molecular Detection of Influenza568 Viruses.
- 2017.https://www.who.int/influenza/gisrs_laboratory/WHO_information_for_the_molecular
 detection of influenza viruses 20171023 Final.pdf
- 57151West Jr. KP, Shamim AA, Labrique AB, *et al.* Efficacy of Antenatal Multiple Micronutrient572(MM) vs Iron-Folic Acid (IFA) Supplementation in Improving Gestational and Postnatal
- 573 Viability in Rural Bangladesh: The JiVitA-3 Trial. *FASEB J* 2013;**27**:358.6-358.6.
- 574 doi:10.1096/fasebj.27.1_supplement.358.6
- 575 52 Kim JM, Labrique A, West KP, *et al.* Maternal morbidity in early pregnancy in rural northern
 576 Bangladesh. *Int J Gynaecol Obstet* 2012;**119**:227–33. doi:10.1016/j.ijgo.2012.06.022

- 577 53 World Health Organization (WHO). Haemoglobin concentrations for the diagnosis of 578 anaemia and assessment of severity. Geneva, Switzerland: 2011. 579 https://www.who.int/vmnis/indicators/haemoglobin.pdf
- 580 54 Ahsan H, Chen Y, Parvez F, *et al.* Health Effects of Arsenic Longitudinal Study (HEALS):
- 581 description of a multidisciplinary epidemiologic investigation. *J Expo Sci Environ Epidemiol*
- 582 2006;**16**:191–205. doi:10.1038/sj.jea.7500449
- 583 55 Rahman A, Vahter M, Ekström E-C, *et al.* Association of arsenic exposure during 584 pregnancy with fetal loss and infant death: a cohort study in Bangladesh. *Am J Epidemiol*
- 585 2007;**165**:1389–96. doi:10.1093/aje/kwm025
- 58656Navas-Acien A, Francesconi KA, Silbergeld EK, et al. Seafood intake and urine587concentrations of total arsenic, dimethylarsinate and arsenobetaine in the US population.
- 588 *Environmental Research* 2011;**111**:110–8. doi:10.1016/j.envres.2010.10.009
- 589 57 Huhmann LB, Harvey CF, Navas-Acien A, *et al.* A mass-balance model to assess arsenic 590 exposure from multiple wells in Bangladesh. *J Expo Sci Environ Epidemiol* 2021;:1–9.
- 591 doi:10.1038/s41370-021-00387-5
- 592 58 Semmes EC, Chen J-L, Goswami R, *et al.* Understanding early-life adaptive immunity to 593 guide interventions for pediatric health. *Frontiers in Immunology* 2021;**11**:3544. 594 doi:10.3389/fimmu.2020.595297
- 595

596

597 **TABLES AND FIGURES**

598 Figure 1. Map of the Pregnancy, Arsenic, and Immune Response (PAIR) Study area within the 599 JiVitA Maternal and Child Health and Nutrition Research Project in northern Bangladesh, 600 indicating the original study area (dark gray), extensions to the study area to achieve the target 601 sample size in the same influenza season and before the Ramadan fast (light gray), and 602 remaining JiVitA area (white). Sector boundaries are represented by light gray lines. Clinical 603 centers where biospecimen collection was performed are noted by black circles. Major roads are 604 indicated by black lines. The inset indicates the approximate location of the PAIR Study (black 605 square) in Bangladesh.



Figure 2. Eligibility and enrollment in the Pregnancy, Arsenic, and Immune Response (PAIR)
Study, Gaibandha District, Bangladesh, 2018-2019. We conducted pregnancy surveillance from
July 2018 to February 2019 and enrolled eligible pregnant women from October 2018 to March
2019. *Initially, pregnant women were eligible at 13-14 weeks of gestational age (GW). In
November 2018, we expanded eligibility to 13-16 GW.



- 613 **Figure 3.** Tube well water arsenic (wAs) and urinary inorganic, monomethyl (MMA), and dimethyl
- 614 (DMA) arsenic, and their sum ($\sum uAs$), plotted on a common log scale, among pregnant women
- 615 at enrollment in the Pregnancy, Arsenic, and Immune Response (PAIR) Study, Gaibandha
- 616 District, Bangladesh, 2018-2019.



Figure 4. Tube well water arsenic (wAs) and the sum of urinary inorganic, monomethyl, and dimethyl arsenic ($\sum uAs$), plotted on a common log scale, among pregnant women at enrollment in the Pregnancy, Arsenic, and Immune Response (PAIR) Study, Gaibandha District, Bangladesh, 2018-2019. A generalized additive model smoother is shown by the solid line. Drinking water arsenic standards for the World Health Organization (10 µg/L) and Bangladesh (50 µg/L) are indicated by dashed vertical lines.



624